Pure Global AI
NCT06221800Recruiting

Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects

A Pilot Study to Assess the Diversity of Gut Microbiome in Metastatic Non-Small Cell Lung Cancer (NSCLC) in Correlation to Treatment Effects and Adverse Effects
University of California, IrvineClinicalTrials.govdiagnostic test
Verified
Study focus
Disease/Condition
Non Small Cell Lung Cancer
Drug/Device/Intervention
Microbiome
Study type
Observational
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
University of California, Irvine
Location
Orange, United States of America
Timeline & enrollment
Phase
N/A
Start date
Jan 31, 2024
End date
Dec 01, 2025
Enrollment
82 participants
Primary outcome

Gut microbiomes in advanced/metastatic NSCLC patients

Summary

This is a pilot study collecting data on the diversity and composition of gut microbiomes in
 subjects with advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) while receiving
 treatment for NSCLC.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06221800
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06221800 through Pure Global AI's free database. This phase not specified trial is sponsored by University of California, Irvine and is currently Recruiting. The study focuses on Non Small Cell Lung Cancer. Target enrollment is 82 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.